Attendee search 

Stephanie Léouzon is Partner and Head of Europe for Torreya Partners, a life sciences boutique advisory firm which she joined in 2012. Previously she worked in healthcare investment banking in the US and Europe from 1989 to 2010, most recently at Credit Suisse in London as a Managing Director and Senior Advisor.

She has advised life sciences clients on more than 25 strategic transactions, valued at over
$65 billion, and has been involved in over 45 financing transactions to provide over $10 billion to healthcare clients.

Stephanie earned an MBA degree from the Darden Graduate School of Business at the University of Virginia in 1989 and a BA degree, cum laude, from Mount Holyoke College in 1985.

John has over 30 years of experience in management consulting and creating value with pharmaceutical and medical product companies.

He founded Novasecta in 2003 and has built the company by selecting and developing top quality consultants who work successfully with clients across R&D, corporate/business development and commercial disciplines. John has directed many strategic and management initiatives, achieving amongst others, strategic organisational change, major licensing deals, corporate transformation, optimised asset portfolios, and improvements in strategic partnerships.

Anna leads Deloitte’s Integration & Separation Advisory (I&SA) team in Switzerland and the EMEA Centre of Excellence for Life Sciences I&SA. Anna is recognized as one of the foremost integration advisors in EMEA and has supported over 30 integrations and separations including many landmark deals. She provides advice and challenge to senior management and boards in planning and delivering complex cross-border integrations and operational carve outs.

Colin is a Director and a key leader in our UK / Swiss Life Science practice. He has been with Deloitte since 2011 working in the US firm until 2014 when he moved to the UK.

Colin’s client advisory work in the Life Sciences sector ranges across strategy and operations focused on the R&D function including operating model development and implementation as well as post-merger integration (PMI). These engagements have been serving client Boards and their senior leadership teams in R&D, Commercial and Supply Chain

Colin is an author of our annual R&D productivity analysis study which reviews productivity of the worlds largest pharmaceutical businesses.

Recent engagements include leadership of the R&D integration workstream for a Med Tech merger leading the European team as well as global responsibility for the R&D and Manufacturing footprints; and design of a new Pharma vaccine R&D model post integration

Colin has a B.Sc (Hons). in Microbiology from the University of London, Queen Mary & Westfield and a Marketing Diploma from the Chartered Institute of Marketing.